|
Researchers seek patient input on study design:
The PI's of this proposed study are including advocates on the planning team, and patient input -- from the very beginning. They are asking several important unanswered questions, so the results will help inform women about the best treatment choices for each individual (and they are including HER2+ cancers in their inclusion criteria). Please consider sharing this invitation on social media and your email lists:
We invite you to help us design a study for breast cancer patients with 1-3 positive lymph nodes by taking a short 12-question survey about your own experiences and the choices that you have made for your treatment for breast cancer. Your answers will help us design our study in a way that is focused on real patient concerns. Thank you for your time!
https://redcap.mskcc.org/surveys/?s=NCAKNFFW9L
Thanks in advance,
Debbie Laxague
__________________
3/01 ~ Age 49. Occult primary announced by large (6cm) axillary node, found by my husband.
4/01 ~ Bilateral mastectomies (LMRM, R elective simple) - 1.2cm IDC was found at pathology. 5 of 11 axillary nodes positive, largest = 6cm. Stage IIIA
ERPR 5%/1% (re-done later at Baylor, both negative at zero).
HER2neu positive by IHC and FISH (8.89).
Lymphovascular invasion, grade 3, 8/9 modified SBR.
TX: Control of arm of NSABP's B-31 adjuvant Herceptin trial (no Herceptin, inducing a severe case of Herceptin-envy): A/C x 4 and Taxol x 4 q3weeks, then rads. Raging infection of entire chest after small revision of mastectomy scar after completing tx (significance unknown). Arimidex for two years, stopped after second pathology opinion.
2017: Mild and manageable lymphedema and some cognitive issues.
|
Linear Mode
